Evidence map›Paper›PMID 40662950›Full record

ArticleeLife2025

Opposing regulation of TNF responses by IFN-γ and a PGE2-cAMP axis that is apparent in rheumatoid and immune checkpoint inhibitor-induced arthritis human IL-1β+ macrophages.

Upneet K Sokhi, Ruoxi Yuan, Bikash Mishra, Yurii Chinenov, Anvita Singaraju, Karmela K Chan, Anne Bass, Richard D Bell, Laura Donlin, Lionel B Ivashkiv

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Upneet K Sokhi *HSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.ORCID https://orcid.org/0000-0001-5907-5646
Ruoxi Yuan *HSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.
Bikash Mishra *HSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.
Yurii Chinenov *HSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.
Anvita SingarajuHSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.
Karmela K ChanDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States.
Anne BassDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States.
Richard D BellHSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.
Laura DonlinHSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.
Lionel B IvashkivHSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, United States.ORCID https://orcid.org/0000-0002-9951-0646

Funding

STEROID THERAPY AND CYTOKINES IN RHEUMATIC DISEASESR01AI046712 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 2000 to 2025
$12.5M
CYTOKINE REGULATION OF RA SYNOVIOCYTE PHENOTYPER01AR046713 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 1999 to 2025
$8.3M
Fc Receptors &Cytokine Balance in Rheumatoid ArthritisR01AR050401 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Lionel B Ivashkiv · 2004 to 2026
$7.4M
Macrophages in human autoimmune tissue pathologyR01AI148435 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI Laura T. Donlin · 2020 to 2026
$2.8M
National Institute of Allergy and Infectious Diseases AI046712NIAID NIH HHS R01 AI046712NIAID NIH HHS R01 AI148435NIAMS NIH HHS AR046713NIAMS NIH HHS AR050401NIAMS NIH HHS R01 AR046713NIAMS NIH HHS R01 AR050401
6 · The paper itself

Abstract

IL-1β-expressing macrophages have been described in rheumatoid arthritis (RA), immune checkpoint inhibitor-induced inflammatory arthritis (ICI-arthritis), and pancreatic cancer and proposed to be pathogenic. IL-1β+ macrophages express genes cooperatively induced by PGE2 and TNF signaling, but mechanisms that induce these cells are not known. We used an integrated transcriptomic and epigenomic analysis in primary human monocytes to study PGE2-TNF crosstalk, and how it is regulated by IFN-γ, as occurs in RA synovial macrophages. We identified a TNF + PGE2 (TP) induced gene expression signature that is enriched in IL1β+ RA and ICI-arthritis monocytic subsets, and includes genes in pathogenic IL-1, Notch and neutrophil chemokine pathways. ICI-arthritis myeloid cells mapped primarily onto four previously defined RA synovial monocytic clusters, and TP genes were expressed in a manner suggestive of a new functional monocyte subset. TP signature genes are distinct from canonical inflammatory NF-κB target genes such as

Indexed as

Arthritis, RheumatoidDinoprostoneImmune Checkpoint InhibitorsInterferon-gammaInterleukin-1betaMacrophagesTumor Necrosis Factor-alphaHumansMonocytesSignal TransductionDinoprostoneImmune Checkpoint InhibitorsInterferon-gammaInterleukin-1betaTumor Necrosis Factor-alphahumanimmune checkpoint inhibitionimmunologyinflammationinterferon gammamacrophagesmouserheumatoid arthritistumor necrosis factor

Identifiers

PMID40662950
PMCPMC12263154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.